Swiss pharmaceuticals giant Novartis says a no-deal Brexit could hurt patients and that it is stockpiling medicines in the UK to help ensure continuity of supply.
This content was published on
1 minute
swissinfo.ch/jc
In a press release on Friday, it said that after the British parliament’s rejection of Prime Minister Theresa May’s Brexit deal, “the risk of UK exiting the EU without a deal is increased and this will be hugely impactful for patients, particularly around the supply and safety of medicines”.
And it called for the British government to take action on medicines.
“It is vital that Government makes minimising disruption to the medicines supply the highest priority as it prepares for a potential hard or disorderly Brexit and ensures cooperation over medicines regulation in this event.”
The pharma giant said it is prioritising measures to ensure that patients in the UK can access medicines produced by Novartis and its Sandoz and Alcon affiliates. It imports some 120 million packs of medicines to the UK from Europe each year, according to the press release.
Novartis also urged the National Health Service and pharmacists in the UK to heed advice not to stockpile medicines, “so supply can be managed centrally, minimising the risk of medicine shortages across the UK”.
Novartis, maker of neurological, immunology and cancer drugs, employs around 1,500 people in the UK.
More
More
Brexit worries to keep Theresa May away from Davos
This content was published on
UK Prime Minister Theresa May, citing domestic concerns, has followed her French and American counterparts by pulling out of this year’s WEF.
What do you think Switzerland’s Alain Berset can bring to the Council of Europe?
The former interior minister is to become the first Swiss Secretary General of the Council of Europe – which issues should his five-year term focus on?
Swiss air traffic control upgrade slows tempo for safety reasons
This content was published on
The upgrade of Switzerland’s air traffic control system will take longer than anticipated following a series of malfunctions.
Switzerland remains ‘world’s most innovative country’
This content was published on
Switzerland remains the world's most innovative country, still ahead of Sweden and the US on the WIPO Global Innovation Index.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis weighs reinsurance tie-up to fund ultra-expensive drugs
This content was published on
Swiss drugmaker Novartis is exploring working with the global reinsurance industry to help bear the cost of new personalised therapies.
Too few pharma companies prioritise access to medicines
This content was published on
Novartis and Roche both get a boost in the 2018 ranking of progress in expanding access to medicines by the biggest pharmaceutical companies.
This content was published on
Sandoz Inc. and Pear Therapeutics announced that that an app to help treat opium addicts was approved in the United States.
The pharma holy grail: drugs for you, designed by you
This content was published on
In the age of sensors, wearables, and artificial intelligence (AI), almost everything can be customised for the individual.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.